Hepatocellular Carcinoma: Prevention and Therapy
Hepatocellular carcinoma (HCC) is an aggressive malignancy of the liver and occurs most often in the setting of chronic liver disease. The most common acquired causes for this are chronic viral hepatitis infections (mostly HBV and HCV), and alcohol. Other causes include nonalcoholic fatty liver disease–related nonalcoholic steatohepatitis, autoimmune liver disease, and biliary diseases. In addition, certain heritable diseases like hemochromatosis and α-1-antitrypsin deficiency can also lead to HCC. Therefore, prevention of HCC can be achieved by preventing and controlling these problems. For treatment, curative modalities are surgical resection and liver transplantation. However, most patients are not candidates for these surgical maneuvers, and outcomes are poor. New therapeutic developments have brought some improvement with both local and systemic disease control.
KeywordsHepatocellular carcinoma (HCC) Hepatitis B virus (HBV) Hepatitis C virus (HCV) Nonalcoholic steatohepatitis (NASH) Cirrhosis Prevention Vaccine Resection Transplantation Ablation Transarterial chemoembolization (TACE) Chemotherapy Sorafenib
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Kudo M. Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology;78 Suppl 1:1–6.Google Scholar
- 7.Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat;17:435–43.Google Scholar
- 10.Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.PubMedCrossRefGoogle Scholar
- 14.• AASLD Practice Guideline. Management of Hepatocellular Carcinoma: An Update. American Association for the Study of Liver Diseases., 2010. (Accessed October 31, 2010. at http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf.). Updated guidelines on HCC management, by the American Association for Study of Liver Diseases.
- 17.• Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol;21 Suppl 5:v59-64. Updated guidelines on HCC management, by the European Society for Medical Oncology. Google Scholar
- 21.• Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009;9:31. Meta-analysis showing that RFA is better than ethanol injection as local therapy for HCC; although individual studies are somewhat heterogeneous, better survival was seen with RFA. PubMedCrossRefGoogle Scholar
- 27.Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol;33:41–52.Google Scholar
- 28.Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology;52:762–73.Google Scholar
- 30.Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology;138:52–64.Google Scholar
- 31.• Benson AB, 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350–91. Updated guidelines on HCC management, by the National Comprehensive Cancer Network. Chemotherapy is not recommended outside of a clinical trial. PubMedGoogle Scholar
- 32.Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother;11:1943–55.Google Scholar
- 33.•• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. This is the landmark randomized controlled trial of sorafenib versus placebo, showing an improvement in overall survival with sorafenib in advanced HCC. PubMedCrossRefGoogle Scholar
- 34.•• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. This is the second randomized controlled trial of sorafenib versus placebo showing an improvement in overall survival with sorafenib in advanced HCC. Conducted in a different geographic area, results were not as striking as in the SHARP trial, however. PubMedCrossRefGoogle Scholar
- 39.• Qin S, Bai, Y., Ye, S., et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010;28:abstr 4008. Interesting preliminary results were seen in this randomized controlled trial: an improvement in overall survival with combination chemotherapy for advanced HCC. Final results are eagerly awaited. Google Scholar
- 43.Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981–6.Google Scholar
- 44.Sun W, Sohal D, Haller D, et al. Phase II Trial of Bevacizumab, Capecitabine and Oxaliplatin in Treatment of Advanced Hepatocellular Carcinoma. CA Cancer J Clin 2010.Google Scholar
- 46.Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma: A Randomized Trial. JAMA. 2010;304:2154–60.Google Scholar
- 47.• Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol;28:3994–4005. This report highlights the current practice standards for HCC treatment and outlines the major research questions that need to be answered, along with information on ongoing clinical trials that are addressing some of these questions. Google Scholar